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Functional in vivo Screen Identifies PYGO2 as a 
Putative Gene to Promote Prostate Cancer 
by 
Xiaolu Pan, MB 
 
Poor prognosis of prostate cancer is correlated with rampant chromosomal 
copy number alterations, highlighting the potential function of genes with 
copy number gains and losses in driving prostate cancer progression. To 
identify putative genes promoting prostate cancer, an in vivo 
tumorigenesis screen was performed for 286 genes that are recurrently 
amplified and overexpressed in human prostate cancer. The transcription 
co-activator protein PYGO2 was identified as a major hit for further in vivo 
functional and clinical validation. Overexpression of PYGO2 could 
enhance primary tumor growth as well as local invasion to lymph nodes 
using AR-positive prostate cancer cell line LNCaP. PYGO2 may mediate 
its pro-tumor function through upregulation of genes including WNT2, 
ADAMTS2, IGFBP3 and downregulation of KISS1. Tissue microarray 
analysis indicated that PYGO2 upregulation was correlated with higher 
Gleason score in prostate cancer. Collectively, the results suggest PYGO2 
as a potential prognostic marker as well as a therapeutic target. Additional 
functional characterization of PYGO2 in prostate cancer pathogenesis is 
warranted and ongoing.  
vi 
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Chapter 1 Introduction  
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1.1 Introduction 
Prostate cancer (PCa) is the most common non-cutaneous cancer in men.  
In 2013, around 238,590 new cases and 29,720 related deaths were reported 
(Siegel et al., 2013). Several decades of PCa research has helped to delineate the 
core progression pathways for human PCa, which sequentially develops from 
normal epithelium, to prostatic intraepithelial neoplasia (PIN), to  latent and then 
clinically manifested adenocarcinoma, and ultimately to distant metastases 
especially to bone and also to other organs (Figure 1.1) (Shen and Abate-Shen, 
2010b). Accompanying the key histopathological features are some well 
characterized molecular changes such as TMPRSS2-ERG translocation, PTEN 
inactivation and EZH2 overexpression. Despite the pathological and molecular 
understanding, current effective therapies for PCa are largely limited to androgen 
deprivation therapy (ADT) with an initial success rate of close to 90%. However, 
most PCa patients develop refractory disease to surgical or chemical castration, 
resulting in the development of castration resistant prostate cancer (CRPC) with 
high morbidity and mortality. Therefore, there remains a critical need for better 
understanding the etiology of aggressive PCa, in particular, the identification of 
bona fide PCa genes and specific molecular mechanisms that may potentially 
generate new therapeutic interventions.  
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 Figure 1.1 Currently histopathological and molecular genetic model of PCa development. Taken from (Shen and 
Abate-Shen, 2010) with permission from Cold Spring Harbor Laboratory (CSHL) Press 
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Recent genomic profiling of various cancer types, in particular efforts 
triumphed by The Cancer Genome Atlas (TCGA), has revealed that different 
cancer types displaying distinct mutation rates.  Compared to cancers such as 
melanoma and lung cancer, PCa has a relatively low mutation rate. It highlights 
the potential implication of other types of genetic or epigenetic alternations in 
driving cancer progression (Lawrence et al., 2013). The clinical significance of 
genomic instability in promoting PCa was indicated by the observed correlation of 
rampant genomic gains and losses with poor prognosis, while transcriptomic 
profiles were unable to provide significant prognostic value(Taylor et al., 2010) 
Therefore, a critically important research direction for dissecting PCa genetics 
would be the identification of driver genes that are embedded in the amplified or 
deleted peaks of the PCa genomes. My thesis project was set to address this 
question by taking a genome-informed functional screen approach, in particular, 
an open-reading frame (ORF) screen in mice for genes that are recurrently 
amplified and overexpressed in PCa genomes. 286 genes were screened for their 
functional contribution to promoting prostate tumorigenesis in mice. Several hits 
are identified and in the stage of further validation and characterization. In 
particular, the major focus of this study is on PYGO2 which may function as a 
tumor-promoting gene and may serve as a potential prognostic marker based on 
my preliminary data. 
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1.2 Anatomy of human and mouse prostate 
Prostate gland is a walnut-sized male sex hormone regulated organ. It is 
located at the base of the bladder, surrounding the urethra. Prostate gland 
secretion usually constitutes 50-75% of the volume of the semen (Leo Shedlovsky, 
1942). The mouse prostate is lobular with anterior (AP), ventral, dorsal, and lateral 
prostate. The last two lobes commonly combine as dorsolateral prostate (DLP) 
(Abate-Shen and Shen, 2002). Unlike the mouse prostate, the human adult 
prostate lacks clear lobular structure but consists of a zonal architecture. Central, 
periurethral transition, and peripheral zones as well as an anterior fibromuscular 
stroma constitute the prostate. Specifically, peripheral zone occupies ~70% of the 
prostate volume and harbors the majority of PCa. Most of the benign prostatic 
hyperplasia (BPH) arises from the transition zone.  
1.3 The biology and progression of PCa 
The heterogeneity of PCa is illustrated by the multifocal events in primary 
tumors. The neoplasm often contains multiple genetically-independent histologic 
foci that commonly attribute to the multi-event neoplastic transformation that 
parallels aging. The earliest initiation in men can be as early as 20 years of age 
(Sakr et al., 1994; Yatani et al., 1989). While some foci progress to clinical 
detectable cancerous lesion, latent PCa remains inactive likely due to a lack of 
certain genetic events that lead to an aggressive behavior.  
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High-grade prostatic intraepithelial neoplasia (PIN) refers to abnormal 
proliferation with no stromal invasion (Bostwick, 2000). Though some 
controversies exist (DeMarzo et al., 2003), high-grade PIN is generally accepted 
as a pre-invasive stage for PCa (Bostwick, 2000). The aggressive lesions may 
progress to PCa, marked by pathologically absent  basal cell layer(Bostwick et al., 
2004). Remote metastasis follows invasion, mostly located in bone (90%) 
(Bubendorf et al., 2000). Surgical or chemical ADT are applied but almost all 
patients develop CRPC eventually (Felici et al., 2012). Notably, metastases from 
the same patient maintain a signature pattern of copy number, mutation status, 
erythroblast transformation specific rearrangement methylation, and 
phosphorylation (Aryee et al., 2013; Drake et al., 2013; Grasso et al., 2012; Liu et 
al., 2009; Mehra et al., 2008). 
As a cancer type with inherent heterogeneity, PCa relies on a unique scoring 
system to inform diagnosis and prognosis(Gleason, 1992). PCa , especially 
prostatic glandular carcinomas, is graded by Gleason system according to the 
histomorphological appearance of biopsies (Mellinger et al., 1967). Five basic 
grade patterns from 1 to 5 represent the extent of glandular differentiation. Two 
scores are summed with the first score, assigned to the dominant pattern 
(occupied more than 50%), and the one second score, assigned to the next-most 
frequent pattern (less than 50%). Histological grading of Gleason score is by far 
the most prevailing indicator for clinical outcome of patients(Humphrey, 2004). It is 
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proved by multiple studies linking it to the overall survival of PCa (Gonzalgo et al., 
2006; Melissari et al., 2006).  
1.4 Subtypes of PCa  
 It is notable that PCa lacks distinguishable histopathological subtypes that 
could guide its prognosis or treatment response; compared to other epithelial 
tumors, such as breast cancer or lung cancer. Most cases of the PCa are acinar 
adenocarcinomas that express AR. Other categories of PCa are extremely rare; 
such as ductal adenocarcinoma, mucinous carcinoma, and signet ring carcinoma 
(Grignon, 2004). Neuroendocrine small cell carcinomas representing <2% of PCa 
cases are generally classified as either small cell carcinoma or carcinoid tumor. 
1.5 PCa genomics and amplified genes.  
Large-scale genomic analysis characterizes genetic alterations in PCa. 
These alternations, including point mutations, deletions, re-arrangements and 
amplification, contribute to multi-steps of tumorigenesis. 
PCa genome harbors relatively moderate number of point mutations (Berger 
et al., 2011; Taylor et al., 2010). Common mutated genes in other tumor types, 
including TP53, PTEN and KRAS, usually are not frequently observed in PCa 
genome (Taylor et al., 2010). TMPRSS2:ERG gene fusions are consistently to be 
reported in about 50 percent of clinically localized PCa samples (Kumar-Sinha et 
8 
 
al., 2008). The most frequent alteration in PCa genome is loss of chromosome 8q, 
harboring NKX3.1. Some significant deletion peaks target PTEN, RB1 and TP53 
(Taylor et al., 2010). While the mutation rate for PCa is moderate, genomes of 
more aggressive PCa and CRPC are featured by rampant chromosomal instability 
(Taylor et al, Grasso et al). Genomic gains can have functional consequences, as 
evidenced by known cancer genes altered by amplification which leads to 
overexpression  (Santarius et al., 2010). For example, a frequently amplified region 
in cancer genome, 8q24.21 which encompasses MYC and NCOA2, is also among 
the most amplified regions in aggressive PCa (Taylor et al). It is also of interest to 
note AR (Xq12) amplification in metastatic CRPC (Grasso et al). An unanswered 
question remains, as to what other genes involved in these chromosomal gains 
functionally contribute to the progression of PCa.  
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Chapter 2 Functional in vivo screen 
identifies putative drivers of prostate 
cancer 
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2.1 Introduction 
Increasingly high-resolution genomic studies with next-generation 
sequencing (NGS) technology reveal recurrent focal deletions and amplifications 
in cancer genome (Chin et al., 2011; Yates and Campbell, 2012). For prostate, a 
handful of large-scale genomic profiling studies have been reported, including 
Taylor et al. (MSKCC dataset), Grasso et al (Michigan dataset), Barbieri et al 
(Harvard dataset). A large portion of genomic data of prostate cancer TCGA can 
be downloaded and analyzed, although the paper on prostate cancer TCGA has 
not been published yet. From these datasets, putative amplified gene list was 
compiled. It was expected some of the genes on the list should play functional 
roles in promoting prostate tumor progression, and through a proper selection of a 
mouse model system which had low tumor formation background by the tumor cell 
line alone, potential driver genes on the list could be identified.  
Following this rationale, we performed genome-informed in vivo screen, and 
41 hits were identified. The mechanisms for promoting PCa progression of the top 
12 amplified genes were further analyzed. Moving the project forward PYGO2 was 
set as focus based on the following reasons: 1) overexpression of PYGO2 induced 
anchorage-independent colony formation in LHMK cell line; 2) PYGO2 promoted 
in vitro migration and invasion of LHMK cell line; 3) Recent studies in development 
biology has suggested PYGO2 as an important gene regulating stem cell function 
11 
 
and tissue homeostasis in skin and mammary and spermiogenesis (Gu et al., 2013; 
Nair et al., 2008; Sun et al., 2014).  
Pygopus was first reported as an essential transcription co-activator with 
Arm/β-catenin-Tcf complex for Wnt signal transduction pathways in Drosophila 
(Belenkaya et al., 2002). Two mouse and human pygopus genes Pygo1 and Pygo2, 
have been identified. The later expressed in a broader range of adult and 
developing tissue consistent with the Wnt signaling activity to regulate proper 
development and maintenance(Li et al., 2004). In contrast with Pygo1 null mice, 
Pygo2 null mice presented serious developmental defects like lens agenesis and 
a kidney phenotype with high penetrance, exencephaly, and cleft palate 
incomplete penetrance and exhibit perinatal lethality (Li et al., 2007; Schwab et al., 
2007).  
PYGO2 has highly conserved plant homeodomain (PHD) in its C-terminus 
that is associated with histone modifications (Miller et al., 2013). It was reported to 
directly bind to histone H3 (Fiedler et al., 2008) (Gu et al., 2013) (Kessler et al., 
2009) and recruited histone-modifying enzymes to generate more H3K4me as 
active histone marks to facilitate transcription (Gu et al., 2009). The recruitment of 
PYGO2 was associated with Wnt pathway activation (Städeli and Basler, 2005) 
and Rb attenuation (Tzenov et al., 2013). Moreover, PYGO2 has also been 
implicated in histone acetylation independent of Wnt signaling (Nair et al., 2008). 
Interestingly, a recent paper reported lncRNA PCGEM1 recruited PYGO2 to 
enhance AR-bound enhancers targeting gene promoters (Yang et al., 2013). 
12 
 
Despite the reported up-regulation in skin (Sun et al., 2014), hepatocellular 
carcinoma (Zhang et al., 2014), and lung cancer (Zhou et al., 2014), the function 
of PYGO2 has not been thoroughly investigated in PCa.  
2.2 Material and methods 
2.2.1 Bioinformatic analysis of global gene expression to determine pro-
progression genes. 
Exome sequencing data is frequently adopted in current study to investigate 
the somatic copy-number amplification in cancer genome. To generate a list for 
putative genes that are recurrently amplified in PCa and also expressed at higher 
level in metastasis than primary tumor, Dr. Xin Lu and Dr. Terrance Wu conducted 
an integrative bioinformatics analysis on four exome sequencing datasets, Grasso 
and colleagues (Grasso et al., 2012), Taylor and colleagues (Aravindaram and 
Yang, 2010), Barbieri and colleagues (Barbieri et al., 2012) and the Cancer 
Genome Atlas (TCGA; Research Networks, https//tcga-
data/nci.nih.gov/tcga/dataAccessMatrix.htm, DOI # 2012-10-04). In the analysis, 
recurrently amplified genes across multiple datasets were further selected based 
on copy number – expression correlation (p<0.01) and displaying higher 
expression level in metastasis compared with primary tumor in at least 3 out of 8 
microarray-based expression datasets from Oncomine® (Figure 2.1) Lu and Wu 
also reasoned that some pro-metastasis genes can be upregulated through non-
amplification mechanisms therefore a separate branch of analysis was applied. 
Genes were selected if they were highly expressed in metastatic compared to 
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primary tumor in 6 out of 8 Oncomine® datasets (Figure 2.1). To elaborate the 
process in more details, majority of the genes are collected to identify the putative 
driver genes at amplicons. The genes at focal amplification peaks were selected 
by GISTIC (Bubendorf et al., 2000) analysis on the previously mentioned prostate 
exome sequencing studies. G-score was set as a cut-off to eliminate unimportant 
passenger alterations. The evaluation of copy number-expression correlation was 
followed to identify the amplified genes correlated with up-regulation. A cutoff was 
also set to spotlight genes more enriched in metastasis comparing to primary sites 
because they are more relevant to aggressive PCa progression. It is based on the 
following criteria: call if p< 0.05 (student t test) in 3 out of 8 expression datasets 
from Oncomine® (https://www.oncomine.org). On the other hand, in order to 
include some of the functionally important genes with high expression levels but 
without discernible amplification cases in analyzed patient samples, we added 
genes based on the following criteria: call if p< 0.05 (student t test) in 6 out of 8 
expression datasets from Oncomine® (https://www.oncomine.org). Following 
these strategies, in total 741 genes were compiled. From the MDA LentiORF 
library, 286 ORFs were available, whose vectors were the reagents for the 
functional in vivo screen  
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Figure 2.1 Bioinformatic genomic analysis to generate amplified/overexpression gene list for PCa progression
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2.2.2 Cell culture 
HEK293T cell were obtained from American Type Culture Collection (ATCC, 
Manassas, VA). LHMK and LHMK-AR cell lines were generous gifts from Dr. Bill 
Hahn’s lab. Cells were cultured in DMEM (Live technologies) with 10% fetal bovine 
serum (FBS) (Live technologies) in a humidified incubator at 37°C in a 5% CO2 
atmosphere. BPH-1 were obtained from American Type Culture Collection (ATCC, 
Manassas, VA) and maintained in RPMI (Live technologies) with 10% FBS (Live 
technologies) in a humidified incubator at 37°C in a 5% CO2 atmosphere. 
2.2.3 Establishment of the library of blasticidin-selected stable cell lines 
overexpressing 286 candidate genes 
The following work flow was used to establish the library of stable cell lines 
overexpressing putative driver genes of PCa. Glycerol stocks contained bacteria 
with desired open reading frames (ORFs) constructs were obtained from MD 
Anderson core. The ORFs were cloned by Gateway cloning to the pLOC vector. 
The pLOC vector contains blasticidin-selection cite and turboGFP as indicated in 
the Figure 2.11. Bacteria were then individually multiplied in 96-well-plate format, 
followed by midi-prep (Qiagen). The result pool was validated by sequencing 10 
clones randomly. High throughout-put normalization to the same concentration 
was conducted by QiAgility (Qiagen) in 96 well plates. Virus packaging was 
achieved to target 286 genes individually. Virus was infected with seeded LHMK 
cells in 96-well plates. 24 hours post-infection, desired clones were obtained by 
blasticidin selection (10ug/mL) for 1 week to maintain the cells while they were 
expanded for 2 passages to acquire enough cell for in vivo injection.  
16 
 
 
Figure 2.2 Workflow of in vivo ORF screen for amplified/overexpressed genes 
Schematic representation of the approach. LHMK cells were infected with single ORFs and injected subcutaneously 
to allow tumor formation with 10 replications. The injection sites on left side of the mice were marked as stars shown in 
the figure.
17 
 
 
 
Figure 2.3 Vector structure for LentiORF library establishment (Taken From 
Thermo Fisher Scientific Inc., Techinical Manual, Thermo Scientific Open 
Biosystems Precision LentiORF Collection) 
2.2.4 Xenograft studies and in vivo ORF screen for putative genes promoting PCa 
All animal experimental protocols were approved by the Institutional Animal 
Care and Use Committees at the University of Texas MD Anderson Cancer Center 
(Houston, TX) (IACUC number: 1169-RN01). Three prostate cell lines, LHMK, 
LHMK-AR and BPH-1, were tested for in vivo tumor formation by intradermal 
injection of 5 X 10^5 cells into the flanks of male nude mice (Taconic). LHMK was 
as parental lines because of the relatively long tumor latencies, which were seen 
no visible subcutaneous tumor formation in 6 months. 1 X 106 cells were injected 
subcutaneously into the 10 sites of each nude mouse. All the injected cells were 
diluted in PBS (Life technologies) and then mixed with BD MatrigelTM basement 
membrane matrix (BD Biosciences).  
18 
 
2.2.5 RNA extraction, cDNA synthesis and quantitative RT-PCR.  
Total RNA was isolated from cells by RNeasy Mini kit (Qiagen). After 
normalization, total cDNA was synthesized by reverse transcription (RT) kit 
SuperScript III as manufacturer’s protocol (12574-026, Invitrogen). Semi 
quantitative PCR was performed to detect the expression level of genes of interest, 
comparing level between negative control and the established cell lines by SYBR 
Green methods (Invitrogen). RPL30 were detected for an internal control for 
normalization purpose. Sequences of primers used for PCR reactions are in 
supplement material  
2.2.6 Genomic sequencing 
Plasmid DNA was prepared by QIAGEN Midiprep kit. Samples were sent to 
MD Anderson Sequencing Core for Sanger Sequencing. The result sequence was 
‘BLAST’ed by NCBI online tool compared with targeting ORF sequence.  
2.2.7 Protein lysate and western blot assays 
Protein lysate of PCa cell lines for the characterization of PYGO2 expression 
level was obtained from DePinho Lab including 22Rv1-TR,  
Cells were lysed and sonicated in RIPA buffer (89901, Thermo) with protease 
inhibitor and phosphatase inhibitor cocktails (Roche). Bradford assay (Bio-rad) 
was applied for quantifying the amount of total protein. Lysates were fractionated 
by sodium dodecyl sulfate (SDS)-PAGE and transferred onto nitrocellulose 
membrane (Invitrogen). The membranes were blocked with 5% nonfat dried milk 
and then incubated with desired primary antibodies dilution in 5% bovine serum 
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albumin (overnight at 4°C. After applying second antibodies, peroxidase-
conjugated anti-rabbit or anti-rabbit IgG, protein bands were detected by 
chemiluminescent detect system (Thermo).  
Primary antibodies used in this project includes monoclonal anti-KRAS 
antibody (sc-30, Santa Cruz), polyclonal anti-PYGO2 (1:1000) (HPA023689, 
Sigma).  
2.2.8 Proliferation analysis 
LHMK cells with overexpression of gene of interest were plated on 24 wells 
plate and assessed of their confluence by IncuCyte® (Essen BioScience) for 7days. 
2.2.9 Soft agar analysis 
2mL bottom agar mixture (DMEM + Glutamax with 1% FBS, 0.6% LE 
Agarose) (Lonza) was applied to coat a 6-well culture plate and solidified in 4°C 
for 1 hour. Cells were trypsinized, counted and diluted to 2X104mL in 2mL top agar 
mixture (DMEM + Glutamax with 1% FBS, 0.3% SeaPlaque ® Agarose) (Lonza). 
Mixture was plate in the top agar and incubated with 2mL desired media at 37°C 
for 3 weeks. At endpoint, crystal violet was used to stain the plate. The colonies 
were quantified by counting 3 representative fields at 4X magnification. 
2.2.10 Migration assay 
Consisting of a 24-well companion plate with inserts containing 8µm pore 
size filters, Cell Culture Insert (BD Falcon) was used for the migration assay. Cells 
were first starved in DMEM with 1% FBS overnight and then seeded onto the 
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inserts in serum-free DMEM at a density of 5X105 cells/200µL. DMEM containing 
10% FBS was placed in outer wells as a chemoattractant. After 12 hours of 
incubation, none-migrating cells were removed with cotton swaps while migrated 
cells were fixed with methanol and stained with 0.2% crystal valet containing 2% 
ethanol. Migrated cells on the entire chamber were observed and counted under 
microscope. 
2.2.11 Matrigel invasion assay 
Matrigel invasion assay were performed applying 8µL pore size BioCoat 
Matrigel Invasion Chamber (BD Falcon) as protocol. Starved with DMEM with 0.1% 
FBS overnight, 5X105 cells were prepared in serum-free 500µL DMEM and then 
added into the chambers. DMEM containing 10% FBS was provided in outer wells 
as chemoattractant. After 18 hours of incubation, none-migrating cells were 
removed with cotton swabs while migrating cells were fixed with methanol and 
stained with 0.2% crystal valet containing 2% ethanol. Invading cells on the entire 
membrane were observed and counted under light microscope. 
2.2.12 Tissue specimen, histology and immunohistochemistry 
Tissue microarray was ordered at US Biomax, Inc as catalog number 
PR803b, the clinical information was listed available online. Patient-derived 
xenograft (PDX) models were generous gifts from Dr. Nora Navone. Transgenic 
mice were generated from DePinho ab. After fixed in 10% formalin overnighted, 
tissues were embedded in paraffin. The primary antibody used in IHC was rabbit 
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anti-PYGO2 ordered from Sigma Aldrich (HPA-023689), which were also used in 
western blot.  
2.2.13 Expression profiling  
RNA was isolated as previous described and sent for profiling at MD 
Anderson Microarray Core facility by the Human Genome U133 plus 2.0 Array 
(Affymetrix).  
2.2.14 Bioinformatic study and statistical analysis 
Gene Set Enrichment Analysis (Subramanian et al., 2005) was conducted as 
User Guide. As recommendation, FDR (False Discovery Rate) q-value<0.025 was 
set as a cutoff for appropriate indicator of gene enrichment. Gene sets collection 
from Kyoto Encyclopedia of Genes and Genomes (KEGG) were included in the 
analysis. Statistical analyses were performed by t test and one-way ANOVA using 
GraphPad Prism 4. In all experiments with error bars, Standard Deviation Ellipse 
(SDE) was calculated to indicate the variation within all replicates. 
2.3 Results 
2.3.1 Identification of putative genes contributing to tumor progression  
741 putative genes were identified as candidates genes associated with PCa 
progression by integrative comparative genomic analysis. Gain of function 
screening experiments were performed using the 286 available expression vectors 
carrying ORFs derived from the above-mentioned list. In order to establish a 
screening system which has low background of tumorigenesis in immunodeficient 
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mice thus facilitating the detection of emergence of tumors formed by ORF 
overexpression, we chose the cell line LHMK. LHMK was derived from a normal 
human prostate epithelial cell line that was transformed with SV40 large T antigen, 
hTERT, PI3K and c-Myc (Berger et al., 2004a). LHMK cells were selected as the 
screen model system because the subcutaneous tumor latency for this cell line in 
nude mice is more than 200 days. Thus it is expected the tumors formed by 
overexpression of any particular ORF would highly likely indicate a real biological 
consequence from a potent pro-tumor gene.  
 Next, 286 ORFs were screened for their in vivo tumor promoting activity. 
Individual lentivirus harboring each of the 286 ORFs was prepared and used to 
infect LHMK cells followed by blasticidin selection for a week. Then, 286 stable 
sublines were generated and maintained to enough number for subcutaneous 
injection (injection sites N=10) (Figure 2.2). The approach of pooling viruses into 
multiple pools and infecting cells followed by injection was not used in our methods. 
Our approach is superior in terms of avoidance of the caveat of tumor phenotype 
emergence due to more than one gene in the same pool and eliminating the need 
for further sub-screen to identify which gene(s) of a pool leads to tumor phenotype. 
I followed tumor growth using caliper measurement and monitored for 226 days 
before all mice without tumors were euthanized. In total, 41 ORFs were identified 
(TTable 2.1). 
As shown in table 2.1, the control line with RFP infection showed no tumor 
growth from 30 injection sites over the observation period. Among the 41 hits, 
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some genes with previously characterized pro-tumor functions in PCa were 
identified (e.g. KRAS, FGFR1, CCNE2, SDC1, EZH2 and AURKA). This result 
supported the validity of the screen system. The in vivo growth patterns of ORF-
mediated tumor promotion varied and ranged from 23-226 days (Figure 2.4). 
Because of practicality, I only validated some but not all of the overexpression at 
RNA levels. Among all 10 tested ORFs, their overexpression were confirmed in 
the sublines (Figure 2.5).  
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No. Replicates Average tumor initiation 
Time (Day) 
Gene name 
0 0 in 30 N/A (LHMK-RFP) 
1 20 in 20 <23 KRAS 
2 1 in 10 23 RBM19 
3 4 in 10 35 MOS 
4 3 in 10 44 FGFR1 
5 1 in 10 46 SLC45A4 
6 1 in 10 46 CDC20 
7 1 in 10 52 BOP1 
8 1 in 10 60 NCBP2 
9 2 in 10 64 CCNE2 
10 1 in 10 64 SDC1 
11 3 in 10 74 TOMM40L 
12 1 in 10 75 PPOX 
13 1 in 10 76 ARL6IP1 
14 2 in 10 85 EZH2 
15 1 in 10 85 ST3GAL1 
16 2 in 10 86 PYGO2 
17 1 in 10 86 IRF5 
18 1 in 10 86 CDCA4 
19 1 in 10 86 WDYHV1 
20 1 in 10 95 TTC35 
21 1 in 10 111 OGFR 
22 2 in 10 120 TAF6 
23 1 in 10 131 CPSF4 
24 1 in 10 152 ATP5G1 
25 5 in 20 153 RPS20 
26 2 in 10 154 MTBP 
27 1 in 10 154 KRTCAP2 
28 1 in 10 154 AURKA 
29 3 in 10 164 ZKSCAN5 
30 2 in 10 167 TROAP 
31 1 in 10 187 POLR2H 
32 1 in 10 187 SPAG1 
33 1 in 10 187 WDR53 
34 1 in 10 187 DERL1 
35 1 in 10 188 ZNF706 
36 1 in 10 189 NUSAP1 
37 1 in 10 205 ESRRA 
38 1 in 10 218 NASP 
39 1 in 10 218 MRPL28 
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Figure 2.4 Representative hits growth of ORFs 
40 1 in 10 216 RRM1 
41 1 in 10 226 MCM7 
TTable 2.1 List of ORFs facilitating LHMK xenograft growth in injected mice in 6 
months 
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Figure 2.5 Representative validation of the expression level of interested 
genes in injected LHMK lines 
Endogenous and exogenous mRNA expression level were validated in LHMK cell lines by 
different primers by qRT-PCR. All expression level were normalized to ∆∆CT to represent 
the relative expression level comparing with RFP-LHMK control. All experiments repeated 3 
times. All error bars are SDM. 
  
 
27 
 
 
The penetrance of the hits indicate their potency to promote the tumor 
progression of LHMK cells. To prioritize hits for further functional analysis, 12 hits 
with at least 2 tumor incidences in 10 injection sites were selected ( 
 
 
 
 
Table 2.2). To discover new putative genes promoting PCa, the genes which 
has been characterized as pro-tumorous genes in PCa (i.e. KRAS, FGFR1, 
CCNE2, and EZH2) will not be validated in all of the following in vitro assays but 
served as positive controls in some of the assays.  
 
 
 
 
 
 
 
Replicates Average tumor initiation time (Day) Gene Name 
0 in 30 N/A (LHMK-RFP) 
20 in 20 <23 KRAS 
4 in 10 35 MOS 
3 in 10 44 FGFR1 
2 in 10 64 CCNE2 
3 in 10 74 TOMM40L 
2 in 10 85 EZH2 
2 in 10 86 PYGO2 
2 in 10 120 TAF6 
5 in 20 153 RPS20 
2 in 10 154 MTBP 
3 in 10 164 ZKSCAN5 
2 in 10 167 TROAP 
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Table 2.2 List of ORFs that promoted multiple tumor growth 
 
2.3.2 Functional validation using cell proliferation assay 
It is possible that some or all of the 12 hits promote tumor growth in vivo by 
enhancing cell division and proliferation. To test this hypothesis, I performed 2D 
growth curve assay using IncuCyte®. However, in preliminary experiments of 9 
hits I observed limited consistent differentiation of the curves when ORFs sublines 
were compared with RFP control line (Figure 2.6). I reason that the lack of 
observed in vitro growth advantage by ORF overexpression was partly caused by 
the already very short doubling time of LHMK (~8h).  
 
Figure 2.6 2D proliferation assays showed similar growth rates among 
LHMK cells overexpressing ORFs 
Growth curve of top hits were obtained by IncuCyte®. Confluence of each lines was 
recorded in multiple time points. All the result was normalized with control lines. 
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2.3.3 Genes promoting anchorage-independent growth 
Since I was not able to obtain proliferation differences in 2D culture, I resorted 
to another approach, the soft agar colony formation assay, which is routinely used 
to explore the anchorage independent growth and often delivers results that are 
more reminiscent of the in vivo growth properties of tumor cells. While the control 
LHMK line was unable to form colonies, several tested hit genes including PYGO2 
showed surprisingly robust colony formation in LHMK cells in 10 days (Figure 2.7). 
It is interesting to note that mechanisms for promoting anchorage independent 
growth by different genes may be through separate pathways, as colonies formed 
by different ORFs displayed different sizes, for example, LHMK-BOP1 and LHMK-
MOS exhibited larger colony size compared with those by LHMK-PYGO2.  
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Figure 2.7 ORFs facilitated anchorage-independent growth of LHMK cells 
a) Overexpression of top hit genes affects anchorage-independent growth in LHMK. Results of soft-agar colony 
formation assays of LHMK sublines. All experiments repeated 3 times. All error bars are SDM. b)  Representative cell 
colonies in soft agar are shown. 
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2.3.4 Functional validation by migration/invasion assay 
Increased mobility and invasiveness are important characteristics of 
malignant tumor cells. In our initial ORF list, the genes are all upregulated in 
metastasis at RNA level across several transcriptome datasets. Therefore, I 
reason that it is possible that one or more of the genes in the hit list may promote 
migration and invasion, properties that could be examined with in vitro Boyden 
chamber assays. Several genes, such as BOP1, MTBP, PYGO2, ST3GAL1 and 
TROAP, showed significant enhancement of migration and invasion in LHMK 
(Figure 2.8).  Although MOS strongly promoted soft agar growth, its effect on 
migration and invasion was lowest in assessed genes.  
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Figure 2.8 Hits showed promoting LHMK in vitro migration (a) and invasion (b) in Boyden chamber assay. 
a & b) LHMK cells overexpressed with hit genes seeded in Boyden chamber were stimulated with FBS. RFP controls 
are highlighted in blue. Experiments were repeated for two independent experiments with three replicates for each. *, 
P<0.05, student t test. All error bars are SDM. c) Migrated or invaded cells were analyzed by light microscope 
(magnification, 4X). 
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2.3.5 Alteration of MAPK pathway activity 
Due to the 100% penetrance of KRAS as being the screen hit, it is of interest 
to assess the ability of the above-tested genes to activate MAPK pathway, the 
prototypical downstream signaling pathway activated by KRAS. Using western blot, 
both KRAS and MOS overexpression induced more pronounced phospho-MEK 
signal, yet both seemed to suppress phospho-AKT signals (Figure 2.9). Given 
MOS being identified as a serine/threonine kinase that activates the MAP kinase 
cascade through direct phosphorylation of the MAP kinase activator MEK (Prasad 
et al., 2008), this result was expected. 
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Figure 2.9 Immunoblotting analysis of various cellular signaling proteins in 
cell lysates of LHMK cells overexpressing ORFs 
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2.3.6 PYGO2 up-regulation was correlated with PCa pathological aggressiveness. 
The expression of PYGO2 in normal prostate tissue and PCa was 
investigated by IHC using LHMK-RFP and LHMK-PYGO2 cell lines as negative 
and positive controls, respectively. PYGO2 staining was clearly localized in the 
nuclei. Notably, the expression of PYGO2 was significantly upregulated in 
adenocarcinoma comparing to that of normal prostate tissue (Table 2.3). Further, 
PYGO2 expression levels in adenocarcinoma patients and their correlation with 
clinicopathological factors were studied. As shown in Figure 2.10, PYGO2 staining 
intensity in prostate tissues was classified in four groups with scores ranging from 
no staining (score 0) to intense staining (score 3). Each sample was scored twice 
with clinical information blind.  
 PYGO2 Expression 
 - + 
Normal 4 0 
Adenocarcinoma 13 54 
Table 2.3 PYGO2 up-regulation in PCa patient samples (n=71) 
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Figure 2.10 Expression intensity of PYGO2 in PCa patient samples from 
low to high (0-4). 
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  PYGO2 expression level  
  IHC intensity score 
p value   0 1 2 3 
  (n=13) (n=24) (n=15) (n=15) 
Stage       
 I+II 6 15 5 6 0.2937  III+IV 7 9 10 9 
T-stage       
 1+2 7 17 6 9 0.2911  3+4 6 7 9 6 
M-stage       
 M0 10 19 8 9 0.2834  M1 3 5 7 6 
Gleason 
Score       
 6-7 5 8 6 0 
0.0274*  8-9 4 10 6 4 
 10 4 6 3 11 
Table 2.4 PYGO2 up-regulation is associated with high Gleason Score 
(n=71) 
As the result shown in Table 2.4, higher PYGO2 expression was significantly 
associated with higher Gleason Score (p=0.0274). However, PYGO2 expression 
was not correlated with tumor staging. PYGO2 expression pattern is being further 
characterized with more samples recapitulating the heterogeneity and multi-stage 
of PCa, including samples of metastatic sites, from MD Anderson pathology bank.  
 Patient-derived xenograft (PDX) model has been increasingly used as a 
preclinical platform due to its more close histopathological and genetic 
resemblance to human disease. When IHC of PYGO2 was performed in four PCa 
PDX models that we obtained from the PDX core run by Dr. Nora Navone at MD 
Anderson, PYGO2 was intensely stained in the nuclei of adenocarcinoma tissues 
in all models (Figure 2.11).  
38 
 
 
Figure 2.11 Representative PDX samples showed strong positive staining 
of PYGO2 
2.3.7 PYGO2 promotes LNCaP local invasion to draining lymph nodes 
To further characterize PYGO2 function in vivo, PYGO2 was overexpressed 
using a lentiviral construct with constitutive GFP marker in LNCaP (Figure 2.12). . 
LNCaP, as an androgen-responsive PCa cell line, was established from a 
metastatic lesion of human prostatic adenocarcinoma (Horoszewicz et al., 1983). 
PYGO2 overexpression boosted the in vivo tumor progression modestly as 
determined by tumor weight at end point (Figure 2.12). Interestingly, while 
metastasis was not observed in parental LNCaP cells, three of the five PYGO2 
overexpressing LNCaP lines developed local invasion to draining lymph nodes 
(Figure 2.13) (Table 2.5).  
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Figure 2.12 PYGO2 enhanced LNCaP subcutaneous tumor progression in 
vivo 
a) Generation of PYGO2 overexpressing lines in LNCaP; b) Tumor weight 
increased in LNCaP overexpressing PYGO2 
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Line Mouse Mets 
LNCaP-
Original 
1 no metastasis 
2 no primary tumor 
3 no metastasis 
4 no metastasis 
5 no metastasis 
LNCaP-
PYGO2 
1 lymph nodes met 
2 lymph nodes met 
3 no metastasis 
4 no metastasis 
5 lymph nodes met 
 
Table 2.5 High penetrance of LNCaP local invasion to draining lymph nodes 
in PYGO2 overexpressed cells 
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Figure 2.13 PYGO2 promotes LNCaP local invasion to draining lymph nodes  
a & b) local s. q. tumor and draining lymph nodes were visualized by bright filed microscopy (BF) and FITC; c) 
histology of primary subcutaneous tumor by HE staining; d) draining lymph nodes were largely overtaken by invading 
tumor cells. 
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2.3.8 Elevated expression of Pygo2 in Wnt-upregulated genetic engineered 
mouse models (GEMMs) and in PCa patients. 
To investigate which signaling pathway is enriched in clinical samples with 
high PYGO2 expression, I collaborate with Dr. Amin Samirkumar to perform Gene 
Set Enrichment Analysis (Subramanian et al., 2005). From at least one publically 
available large-scale transcriptome datasets with both local and metastasis PCa 
samples (Grasso et al., 2012), we observed significant statistical enrichment for 
Wnt signature (http://www.genome.jp/kegg /pathway/hsa/hsa04310.html) in both 
localized (FDR q-value < 0.05064655) and metastatic (FDR q-value < 0.0689247) 
PCa (Figure 2.14). This result suggests that the function of PYGO2 might be 
directly associated with Wnt pathway in PCa patients. 
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Figure 2.14 Wnt pathway enrichment in local (a) and metastasis (b) PCa samples with higher PYGO2 expression 
level at RNA level  
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Knowing that PYGO2 may be related to Wnt pathway in PCa, I took 
advantage of the several GEMM models, including one with prostate-specific APC 
loss, established by Dr. Xin Lu in the lab and evaluated PYGO2 expression pattern 
(Figure 2.15). The expression levels of Pygo2 were elevated in the prostate of PB-
Cre+ PTENL/L mice comparing with wild type, and markedly enhanced in tumors 
from  PB-Cre+ PTENL/L APCL/L mice where there is an expected upregulation of 
Wnt signaling resulted from the deletion of APC gene. This result suggests that 
PYGO2 upregulation may be downstream of Wnt signaling, a hypothesis that is 
being explored in depth by Dr. Lu in the lab.  
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Figure 2.15 Pygo2 IHC on anterior and dorsolateral prostate tissue from wild type, PB-Cre+ PTENL/L and PB-Cre+ 
PTENL/L APCL/L mice 
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Transcriptome profiling identified differential gene expression in PYGO2 
overexpressed LHMK (Figure 2.16). The cutoff was set for a fold change of greater 
than 2.5 times in either direction as shown in Table 2.6. Some of the genes in the 
list were selected for expression validation based on their potential functions in 
cancer after literature study, such as WNT2, KISS1, ADAMTS2, and IGFBP3. 
Their expression levels in LHMK-RFP and LHMK-PYGO2 cells were validated 
(Figure 2.17). In LHMK-PYGO2, the expression levels of WNT2, ADAMTS2 and 
IGFBP3 increased as expected while KISS1 was down-regulated compared to 
those in LHMK-RFP.  
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Figure 2.16 Microarray analysis of LHMK and overexpression cells 
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Fold Change  Regulation ([LHMK‐
PYGO2] vs [LHMK‐RFP]) 
Gene Symbol 
6.62884  Up  CNR1 
4.9924645  Up  COL21A1 
4.917648  Up  ANK3 
4.568018  Up  ZNF804A 
4.339982  Up  SPOCK3 
4.2134004  Up  WNT2 
3.9524667  Up  JPH1 
3.8303087  Up  RARRES1 
3.766973  Up  PCDH10 
3.7488606  Up  RARRES1 
3.7367597  Up  ADAMTS2 
3.6632433  Up  EBF1 
3.5750515  Up  HS3ST3B1 
3.5061955  Up  EBF1 
3.4354672  Up  LDLRAD4 
3.3923466  Up  EBF1 
3.3704123  Up  TNFSF10 
3.3625364  Up  ISL1 
3.3579595  Up  AHNAK2 
3.240252  Up  FRAS1 
3.2399745  Up  COL4A4 
3.2212367  Up  ARHGAP24 
3.1589348  Up  ANK3 
3.13414  Up  LXN 
3.0961728  Up  HMCN1 
3.0851064  Up  PDE8B 
3.048719  Up  PCDH7 
3.0126672  Up  GPC6 
2.9809773  Up  PLCB1 
2.9315355  up  ZFHX4‐AS1 
2.9252326  up  MAN1C1 
2.9163897  up  WISP2 
2.9149344  up  GRIK2 
2.9112802  up  COL3A1 
2.868886  up  TNFSF10 
2.8234982  up  NLGN4Y 
2.8198066  up  TNFSF10 
2.8013465  up  TOX 
2.7908678  up  IGFBP3 
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2.7850227  up  FLRT2///LOC100506718 
2.7831643  up  SPOCK3 
2.7190666  up  C6orf141 
2.71883  up  ITGA4 
2.7138515  up  SYNPO 
2.7098184  up  PCDH7 
2.6812658  up  KAL1 
2.675754  up  DCN 
2.6699352  up  RCAN2 
2.6692655  up  ITGA1 
2.6661928  up  DNER 
2.6522381  up  DCN 
2.6519594  up  ZNF503 
2.6400201  up  PARM1 
2.634583  up  SLC44A5 
2.6236303  up  NFIA 
2.6227007  up  SLC4A4 
2.606458  up  FLRT2///LOC100506718 
2.6019416  up  PELI2 
2.5822084  up  DHRS3 
2.5606158  up  LMO4 
2.5561075  up  CASP1 
2.5494325  up  CLEC3B///EXOSC7 
2.5493717  up  PBX1 
2.5459576  up  TSHZ1 
2.5437036  up  COL3A1 
2.5408363  up  IL7 
2.5340688  up  MAN1C1 
2.5280597  up  FOXA1 
2.5186205  up  LRRC8C 
2.5179226  up  CASP1 
2.5177903  up  MEGF6 
2.511516  up  DKK2 
2.5098848  up  GPRC5B 
2.509565  up  RARB 
2.508565  up  LOC100505946 
2.5054262  up  CASP1 
2.5045822  up  EFNB2 
2.504143  up  IFITM1 
2.5226448  down  DUSP4 
2.5354156  down  REXO2 
2.553761  down  NCAM1 
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2.55806  down  CLMP 
2.5622652  down  USP28 
2.5985959  down  MIR612///NEAT1 
2.625526  down  USP28 
2.6316588  down  MGST1 
2.6578946  down  ZNF883 
2.6836455  down  ATF7IP2///LOC100287628 
2.691571  down  MGST1 
2.723695  down  TMEM47 
2.7501042  down  RARRES2 
2.7749934  down  KISS1 
2.7972617  down  POU3F2 
2.8331623  down  VLDLR 
2.9318223  down  DSC2 
2.9504306  down  PAX6 
2.9601073  down  LOC100506303///LOC100653149///LOC101060483///LOC400
2.9910436  down  OTTHUMG00000175814///RP11‐13L2.4 
3.0252461  down  PDZK1 
3.2035272  down  ND6 
3.249426  down  GAL 
3.2839582  down  DCDC2 
3.2858608  down  MGST1 
3.382219  down  MAP7D2 
3.4408128  down  NRXN3 
3.7098405  down  CADM1 
3.7897563  down  DSC2 
3.8596961  down  NRXN3 
3.9882278  down  PAX6 
4.4886146  down  SYTL5 
4.5460978  down  CNN1 
4.622783  down  CNKSR2 
4.7903833  down  NRXN3 
5.27109  down  CADM1 
5.482167  down  NPPB 
5.779805  down  CADM1 
5.8380966  down  C12orf39 
6.579152  down  CXCL14 
Table 2.6 Up-regulated and down-regulated genes in PCa 
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Figure 2.17 Expression level of WNT2, IGFBP3, ADAMTS2 and KISS1 and 
PYGO2 in LHMK and LHMK-PYGO2 
PYGO2-induced gene expression in LHMK. a) PYGO2 up-regulation in in LHMK 
overexpressed with PYGO2. b) Down-regulation of KISS1 in LHMK overexpressed with 
PYGO2. c) Overexpression of WNT2, IGBP3, ADAMTS2. Bars: mean+SDE (n=3) 
2.3.9 PYGO2 expression in established PCa cell lines.  
For continued validation of PYGO2 function in PCa, PYGO2 expression 
levels in 10 PCa cell lines were characterized. As shown in Figure 2.18, PYGO2 
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is expressed in most PCa lines analyzed. 22Rv1 and PacMetUT cell lines showed 
higher expression levels comparing to the rest.  
 
 
Figure 2.18 Investigation of PYGO2 expression level of PCa cell lines 
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Chapter 3 Discussion and future directions 
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3.1 Discussion 
3.1.1 Functional in vivo screen identify genes with potential to promote PCa 
progression 
Human cancer genome alternations consist of amplifications, indels 
(insertions and deletions) and mutations. Equipped with new cutting-edge tools 
such as exome sequencing and bioinformatics analysis, studies on copy number 
variations nowadays bring new perspective to discover novel bona fide oncogenes. 
In this study, functional in vivo screen advanced the current understanding based 
on cancer genome and transcriptome, collected the information about biological 
function of candidate genes in a high-throughput manner and ultimately pinpointed 
several putative oncogenes potentially playing various roles in multistep PCa 
progression.  
The screen system is proved to be effective, as it successfully identified 
several known oncogenes in PCa, such as KRAS, CCNE2 and EZH2. However, 
in the in vivo screen, 29 out of 41 hits developed only 1 tumor out of 10 replicates. 
As the parental line LHMK for cell library is initially unable to form subcutaneous 
tumor (Berger et al., 2004b), the screen design sets a very high bar to push an 
extremely weakly tumorigenic cell line in nude mice to grow subcutaneous tumor. 
The penetrance of all the hits was general quite low while they were expected to 
play a potent role in PCa progression. Nevertheless, other amplified genes may 
also promote PCa or even be the driver since the screen was only design to identify 
most potent amplified genes in current screen system.  
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To link the hits to the context of PCa genomic and transcriptomic profile, the 
gene amplification and overexpression levels were re-examined in the original 
databases (Table 3.1). Most of the genes showed amplified in multiple databases 
despite that the bioinformatics study also included genes overexpressed without 
known amplification. Most strikingly, most of hits showed amplification in datasets 
from Grasso et al with the biggest number of malignant patients.  
 
Name Amplification 
Taylor TCGA Grasso et al 
MOS   + 
PYGO2   + 
BOP1 +  + 
ST3GAL1 +  + 
MTBP +  + 
ZKSCAN5  +  
TOMM40L   + 
CCNE2 +  + 
Table 3.1 Amplification of prioritized hit in PCa genomic datasets 
Netwalker was used to explore potential interactions among hits in 
collaboration with Dr. Ram Prahald (data not shown). However, no clear 
interactions were shown, which indicated the hits per se rather than synergistically 
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promoted PCa progression. Moreover, it was interesting to note that 6 out of 44 
genes are located on 8q24 chromosome (SLC45A4, BOP1, ST3GAL1, WDYHV1, 
MTBP, and DERL1) but not MYC. It indicates that other genes located at 8q24 can 
also promote PCa progression. I validated some but not all of their effect by in vitro 
assays (BOP1, ST3GAL1, and MTBP). They may act as driver gene working with 
or without MYC in PCa progression. Their potential interactions await in-depth 
study to identify the driver genes as well as to investigating their function in PCa. 
As mentioned above, PYGO2 is selected as an interesting gene for further 
study because of its putative role in driving PCa progression based on its known 
biological functions. At the same time, BOP1 is another gene validated to promote 
sphere-formation, migration and invasion in LHMK cells. However, I was not able 
to find a good BOP1 antibody for western blot. By current commercial available 
antibodies, I am not able to confirm overexpression or knockdown in LHMK-BOP1 
and LNCaP-BOP1 (data not shown), despite in qRT-PCR assays BOP1 
expression levels are manipulated as expected. Moreover, the subcellular 
localization in tissue staining by current commercial available antibodies is 
questionable (data not shown). Thus, BOP1 awaits further study when reagents 
are available, as it can be a possible putative tumor promoting gene. 
3.1.2 Activation of MAPK in PCa 
The link of MOS and wild type KRAS being able to activate pMEK and 
potentiate tumorigenesis of LHMK cells was of particular interest. In PCa, 
RAS/RAF signaling was activated in 43% of primary tumor and 90% of metastases 
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(Taylor et al., 2010). However, it has been shown that KRAS mutation was 
infrequent in PCa (Silan et al., 2012). In fact, recent study that reported that MAPK 
activation could lead to higher tumor grade and metastasis in a transgenic mouse 
model, oncogenic KRAS allele G12D was used instead of overexpression of wild 
type KRAS (Mulholland et al., 2012). Apparently, there was a level of lack of 
understanding how infrequent KRAS mutation can be reconciled with the 
hyperactviated MAPK pathway in PCa. The study shows that wild type KRAS or 
MOS, a MEK kinase, when overexpressed, could lead to higher pMEK signaling 
and higher tumorigenesis. Therefore, it is possible that this result could lead to a 
hypothesis that overexpression instead of oncogenic mutation serves as the 
mechanism for activating MAPK pathway in the context of PCa. 
3.1.3 PYGO2 function in PCa 
Further evaluation of PYGO2 as a hit from the screen has led to several 
interesting findings in functional assays both in vitro and in vivo:  
1) PYGO2 increases sphere formation, invasion and migration of LHMK cells 
(Chapter II) 
2) PYGO2 overexpression in LNCaP increases primary tumor growth and 
local invasion to lymph node(Chapter II) 
3) Dr. Xin Lu’s recent investigation on PYGO2 showed that in vivo silencing 
of PYGO2 with intratumoral injection of siRNA caused tumor shrinkage of one PDX 
model (data not shown).  
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Ongoing studies include assessing if PYGO2 knockdown in PC3 cell line can 
lead to reduced tumor formation in both orthotopic site and as bone metastasis. 
This would be of particular interest to us, as PYGO2 displayed higher expression 
level in metastases than in primary tumor in several ONCOMINE® datasets 
(Figure 3.1). The connection of PYGO2 and Wnt pathway also provides the clue 
that PYGO2 might be involved in bone metastasis, the most frequent metastasis 
type for PCa, as it has been demonstrated by previous studies that Wnt signaling 
plays an important role in osteoblastic bone metastasis of PCa (Ell and Kang, 
2012).  
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Figure 3.1 PYGO2 is upregulated in metastases in several ONCOMINE® 
datasets 
 
3.1.4 PYGO2 upregulation in PCa 
The preliminary assessment of PYGO2 expression in PCa TMA shows that 
PYGO2 is upregulated in PCa and correlated with higher Gleason score. Though 
Gleason score is designed to represent tumor aggressiveness of heterogenetic 
prostate neoplasm, it is preferable to add more cases in current study. We have 
requested three additional TMAs from PCBN, a non-profit organization distributing 
prostate cancer clinical samples to the community. These TMAs include 52 Case 
Lymph Node Mets Array, 200 Case Grade/Stage Array, 217 Biochemical 
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Recurrence (CAP6) and 726 Case PSA Progression Array. While this is exciting, 
it raises the question of how PYGO2 is regulated in cancerous prostate. Based on 
what has been reported about PYGO2 and the above-indicated result, there are 
several possibilities:  
1) PYGO2 is amplified in about 3% of PCa patients, based on an average 
estimate of several PCa genome databases including TCGA 
2) PYGO2 might be upregulated by suppressing RB pathway in PCa. It was 
reported that in cervical cancer, attenuation of RB by HPV virus induces PYGO2 
expression via ELF (Tzenov et al., 2013). RB pathway is among the three most 
altered signaling pathways in PCa (Taylor et al., 2010). Therefore, it is reasonable 
to argue that it is possible that RB pathway inactivation in PCa also induces 
PYGO2 upregulation. This is a possibility that Dr. Xin Lu is investigating.  
3) Other possible explanations for PYGO2 upregulation may include Wnt 
pathway activation and certain microRNA, possibilities that Dr. Lu is investigating 
with Dr. Eun-Jung Jin in the lab.  
3.1.5 PYGO2 mechanism for PCa  
The following working model was proposed based on my current findings 
(Figure 3.2): PYGO2 may promote PCa through both Wnt-dependent and 
independent mechanisms. Both mechanisms are based on the ability of PYGO2 
to bind to histone mark H3K4me and other chromatin regulators. The functional 
output of PYGO2-mediated chromatin regulation includes up-regulation of 
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important cancer related genes such as WNT2 and ADAMTS2 as well as down-
regulation of KISS1. This model is under active investigation by the lab members 
now.  
As identified and validated in various study (Li et al., 2007; Sun et al., 2014), 
loss of function for PYGO2 interferes with Wnt signaling pathways and leads to 
Wnt signaling deficiency. Meanwhile, preliminary study shows overexpression of 
PYGO2 activate Wnt pathways (Schlesinger et al., 2005). In our study, PYGO2 is 
selected for in vivo screen because of its focal amplification in PCa. Amplification 
is a possible mechanism for overexpression(Santarius et al., 2010). By 
amplification and/or by other unknown mechanisms(Bostwick and Qian, 2004), 
PYGO2 may overexpress and to further activate or promote Wnt signaling 
activation in PCa.  
One of the major clinical devastations of PCa is bone metastasis, which is 
the most frequent metastatic sites(Shen and Abate-Shen, 2010a). Wnt signaling 
pathway has been reported to have a key role in bone metastasis (Humphrey, 
2004; Pacelli and Bostwick, 1997; Regard et al., 2012). Besides other mechanism 
involving DKK1(Hall et al., 2005; Thudi et al., 2011), activation of β-catenin induces 
increased bone deposition and decreased osteoclast formation (Glass et al., 2005) 
Autocrine/paracrine activation Wnt signaling are reported in many studies in 
prostate cancer cell lines (Bostwick et al., 1993; Bostwick et al., 1995) and 
PCa(Chen et al., 2004). The exploration of PYGO2 in Wnt signaling especially in 
bone metastasis will provide new insight on this topic. It is of interest to study 
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PYGO2 involvement in such autocrine/paracrine Wnt signaling activation since the 
paracrine/autocrine positive feedback is formed when PYGO2 induces Wnt2 
upregulation in LHMK cell. If it is the case in PCa, PYGO2 will actively induce WNT 
signaling.  
After overexpression, PYGO2 may interfere downstream targets expression 
level by mediating chromatin regulation. The epigenetic study of PYGO2 will be 
conducted collaborating with Dr. Chunru Lin’s group. ChIP assay would be applied 
to investigate PYGO2 mediated protein-DNA interaction.  
To discover the downstream targets of PYGO, unbiased transcriptomic 
profiling is conducted. However, current validated WNT2, ADATMTS2 and KISS1 
are only putative downstream targets. Shown in the results of transcriptomic 
profiling of PYGO2 overexpression in LHMK, other genes may also involve in PCa 
progression. On the list of PYGO-mediated upregulated genes, genes encoding 
collagens are shown to promote cancer advance, such as COL21A1(Abrahams et 
al., 2003) and COL3A1 (Sakr et al., 2000). We will further analyze the gene list 
combined with our results from other cell lines with PYGO2 overexpression and 
knocking-down, since such result will provide genes with epistatic change following 
PYGO2 dysregulation.  
In summary, in my study, putative genes with amplifications and potentially 
promoting prostate cancer progression are identified and validated. Moreover, the 
study on PYGO2 will expand the current understanding of the function and 
mechanism of this specific gene in prostate cancer progression.
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Figure 3.2 Current working hypothesis of PYGO2 in PCa
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